The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study to evaluate the safety and efficacy of RAD001 plus erlotinib in patients with well-differentiated neuroendocrine tumors (NET).
Emily K. Bergsland
Consultant or Advisory Role - Novartis (U); Pfizer (U)
Research Funding - Genentech; Novartis; OSI Pharmaceuticals; V Foundation
Lindsey Watt
No relevant relationships to disclose
Andrew H. Ko
No relevant relationships to disclose
Margaret A. Tempero
No relevant relationships to disclose
Wolfgang Michael Korn
No relevant relationships to disclose
Robin Katie Kelley
No relevant relationships to disclose
Thomas Weber
No relevant relationships to disclose
Iche Siah
No relevant relationships to disclose
Jimmy Hwang
No relevant relationships to disclose
Eric K. Nakakura
No relevant relationships to disclose
Alan Paul Venook
Consultant or Advisory Role - Genentech (U); Novartis (U)
Research Funding - Genentech; Novartis; Roche